Core Viewpoint - The announcement from the company highlights promising preliminary results from the clinical trial of JK06, indicating good safety and efficacy in patients with advanced or metastatic tumors, including non-small cell lung cancer and breast cancer [2] Group 1 - The company, Xinlitai, received notification from its subsidiary, Salubris Biotherapeutics, Inc., regarding the presentation of partial dose escalation data for JK06 at the 2025 European Society for Medical Oncology (ESMO) annual meeting [2] - The preliminary data suggests that JK06 shows good safety and efficacy in patients with unresectable locally advanced or metastatic tumors [2]

Core Viewpoint - Salubris Biotherapeutics, a subsidiary of Xinlitai, presented promising preliminary data on JK06 at the 2025 ESMO conference, indicating good safety and efficacy in patients with advanced unresectable tumors, including non-small cell lung cancer and breast cancer [1] Group 1: Clinical Trial Data - The data presented at ESMO included results from 34 patients with advanced refractory solid tumors enrolled in Europe, all of whom had failed standard treatment options [1] - Among the enrolled patients, 83% had received three or more lines of treatment, and 59% had undergone four or more lines of treatment prior to enrollment [1] - Patients in the dose escalation phase received JK06 treatment every three weeks across five dosage levels ranging from 1.5 to 8.0 mg/kg, with 29 patients undergoing tumor clinical efficacy assessments [1]

Core Viewpoint - Salubris Biotherapeutics, a subsidiary of Xinlitai, presented promising preliminary data on JK06 at the 2025 ESMO conference, indicating good safety and efficacy in patients with advanced solid tumors, including non-small cell lung cancer and breast cancer [1] Group 1: Clinical Trial Data - The data presented at ESMO included results from a Phase I/II clinical trial involving 34 patients with advanced refractory solid tumors, all of whom had failed standard treatment options [1] - Among the enrolled patients, 83% had received three or more lines of therapy, and 59% had undergone four or more lines of treatment prior to enrollment [1] - Patients received JK06 treatment every three weeks across five dosage levels ranging from 1.5 to 8.0 mg/kg, with 29 patients undergoing tumor clinical efficacy assessments to obtain key efficacy data [1]

证券代码：002294 证券简称：信立泰 编号：2025-054 深圳信立泰药业股份有限公司 关于 JK06 境外临床试验进展的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，深圳信立泰药业股份有限公司（下称"公司"）收到子公司美国 Salubris Biotherapeutics, Inc.（下称"Salubris Bio"）的通知，其在 2025 年欧洲肿瘤内科 学会年会（ESMO）展示了 JK06 在 I/II 期临床试验中的部分剂量递增数据。初 步的数据显示，JK06 在包括非小细胞肺癌（NSCLC）和乳腺癌在内的不可切除 的局部晚期或转移性肿瘤患者中，展现出良好的安全性和疗效。现就相关信息公 告如下： 一、JK06 临床试验进展 （3） 在 7 例乳腺癌患者中，1 例经确认达到部分缓解（PR），缓解时间维 持 18 周。 （4） 达到部分缓解（PR）的剂量组，分别为 3.0 mg/kg（1 例 NSCLC）、 4.5 mg/kg（3 例 NSCLC 和 1 例乳腺癌）、6.0 mg/kg（1 例 NSCLC）。 2、在安全性和耐受性方面， ...

Core Viewpoint - The market experienced a correction last week, but certain stocks within the brand index showed resilience, indicating potential investment opportunities in sectors like electronics, new energy, new consumption, and real estate as uncertainties ease [1][4]. Market Performance - The market indices saw declines: Shanghai Composite Index down 1.47%, Shenzhen Component down 4.99%, ChiNext down 5.71%, and CSI 300 down 2.22%. The brand index fell 3.58% to 1956.62 points [2]. - Notable gainers in the brand index included Shanghai Jahwa up 9.42%, Changbai Mountain up 7.19%, and Darentang up 5.34%. Other stocks like Luzhou Laojiao and Yiling Pharmaceutical also saw gains exceeding 4% [2]. Stock Performance Since H2 - Since the beginning of the second half of the year, Zhongji Xuchuang has surged 156.40%, leading the gains, followed by Sunshine Power at 114.27%. Other significant performers include Lanke Technology and Yiwei Lithium Energy, both up over 60% [3]. Market Outlook - Looking ahead, the market is expected to maintain upward momentum as uncertainties gradually diminish. Liquidity is anticipated to remain supportive, with domestic interest rates low and overseas liquidity remaining loose, encouraging investment in Chinese equity assets [4][5]. - The current market environment is characterized by a shift in investment styles, with a focus on sectors that offer higher investment certainty, particularly in electronics, new energy, new consumption, and real estate [5].

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [3] Core Viewpoints - The report emphasizes that the fourth quarter is expected to see a rebound in innovative drugs, driven by a concentration of business development (BD) activities and upcoming events such as the ESMO conference and medical insurance negotiations [4][16] - The Chinese pharmaceutical industry has completed a transition from old to new growth drivers, with innovative drugs significantly opening new growth avenues for Chinese pharmaceutical companies [16][35] - The report suggests that the demand for healthcare will continue to rise due to an aging population, and the payment side is also expected to grow steadily, supported by the development of a multi-tiered payment system [35] Summary by Sections 1. BD + ESMO - The number of license-out transactions in China has been increasing, with 135 transactions occurring from January 1, 2025, to October 17, 2025, totaling $10.2996 billion [8][9] - The report highlights that the international pharmaceutical industry recognizes the value of Chinese innovative drug assets, which are characterized by high quality and low cost [8][9] - The ESMO conference will showcase 23 studies led by Chinese scholars, indicating a significant increase in international recognition of Chinese innovation [12][13] 2. Industry Perspective - The report maintains that innovative drugs will remain the main focus for the year, with attention on manufacturing, overseas expansion, and aging-related consumption [16][35] - The pharmaceutical index has shown a decline of 2.48% in the past week, but an increase of 18.85% year-to-date, indicating a mixed performance [16] - The report lists several companies to watch, including innovative drug manufacturers and those involved in the supply chain [38]

Group 1 - The company received notification from its controlling shareholder, Hong Kong Xinlitai Pharmaceutical Co., Ltd., regarding the release of part of its pledged shares [1][2] - As of the announcement date, the controlling shareholder holds 635.27938 million shares, accounting for 56.99% of the company's total shares [3] - After the release of the pledged shares, the total number of shares under pledge is 97 million, which represents 15.27% of the controlling shareholder's total holdings and 8.70% of the company's total shares [3][4] Group 2 - There are no frozen, marked, auctioned, or trust-set shares held by the controlling shareholder [2][4] - The controlling shareholder has a good credit status and repayment capability, indicating that the risk associated with pledged shares is manageable [4] - The pledge of shares will not lead to a change in the actual control of the company and will not affect its operations or governance [4]

证券日报网讯 10月15日晚间，信立泰发布公告称，公司于近日接到公司控股股东信立泰药业有限公司 的通知，获悉其将所持有的本公司部分股份解除质押，解除质押股份数量为1，700.00万股。 （文章来源：证券日报） ...

Core Viewpoint - The announcement regarding the partial pledge release of shares by the controlling shareholder of Xinlitai has attracted market attention, indicating a positive signal for investor confidence in the company [1]. Summary by Relevant Sections Release of Pledge - Xinlitai Pharmaceutical Co., Ltd. (Hong Kong Xinlitai) has released a total of 1,700,000 shares from pledge, which accounts for 2.68% of its holdings and 1.52% of the company's total share capital [2]. - The released shares include 1,100,000 shares (1.73% of its holdings) and 600,000 shares (0.94% of its holdings), with the pledges initiated on June 13, 2018, and October 11, 2019, respectively, and set to be released by October 14, 2025 [2]. Pledged Shares Situation - As of the announcement date, Xinlitai Pharmaceutical holds 63,527,938 shares, representing 56.99% of the company, with 9,700,000 shares currently under pledge, which is 15.27% of its total holdings and 8.70% of the company's total share capital [3]. - There are no frozen, marked, auctioned, or trust-set shares, nor any non-operational fund occupation or illegal guarantees that could harm the interests of the listed company [3]. Financial Health and Control - Xinlitai Pharmaceutical has a good credit status and repayment capability, indicating that the risks associated with pledged shares are manageable [3]. - The pledge of shares will not lead to any change in the actual control of the company and will not affect its production, operation, or governance [3].

Core Viewpoint - The company, Sinopharm, has received approval from the National Medical Products Administration for its clinical trial application of the innovative small molecule drug SAL0137, which is intended for the treatment of elevated lipoprotein (a) levels [1]. Group 1 - The company announced that it has received the acceptance notice for the clinical trial application of SAL0137 [1]. - SAL0137 is an oral small molecule drug developed by the company with independent intellectual property rights [1]. - The clinical trial application submitted by the company is specifically for the treatment of elevated lipoprotein (a) [1].